Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 1.34 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 347 other companies have achieved higher Quick Ratio than Inflarx N V in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 1795.

Explain Quick Ratio?
How much Cash & cash equivalents IFRX�s has?
What are IFRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IFRX Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q2
Y / Y Current Liabilities Change	-0.85 %	32.53 %	-22.93 %	-22.93 %	-22.27 %
Y / Y Cash & cash equivalent Change	-6.11 %	-12.81 %	5.38 %	5.38 %	12.24 %
Quick Ratio MRQ	1.34	1.34	1.34	1.34	1.42
IFRX's Total Ranking	# 1795	#	#	#	#
Seq. Current Liabilities Change	0 %	0 %	0 %	-0.85 %	33.66 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	-6.11 %	-7.13 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 348
Healthcare Sector	# 629
Overall Market	# 1795

Quick Ratio Statistics
High	Average	Low
1.36	1.23	0.98
(Dec 31 2022)		(Dec 31 2023)

Financial Statements
Inflarx N V's Current Liabilities	$ 15 Millions	Visit IFRX's Balance sheet
Inflarx N V's Cash & cash equivalent	$ 20 Millions	Visit IFRX's Balance sheet
Source of IFRX's Sales		Visit IFRX's Sales by Geography

Cumulative Inflarx N V's Quick Ratio

IFRX's Quick Ratio for the trailling 12 Months

IFRX Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-8.22 %	-13.74 %	-27.5 %	-17.06 %	-5.3 %
Y / Y Cash & cash equivalent TTM Growth	-2.67 %	1.79 %	10.97 %	7.77 %	4.68 %
Quick Ratio TTM	1.34	1.36	1.5	1.38	1.27
Total Ranking TTM	# 4635	#	#	#	#
Seq. Current Liabilities TTM Growth	-0.21 %	6.52 %	-7.33 %	-6.83 %	-6.22 %
Seq. Cash & cash equivalent TTM Growth	-1.6 %	-3.49 %	1.23 %	1.24 %	2.91 %

Quick ratio ranking by company, industry and sector >> Back to IFRX Financial Strength Comparisons >> Go to Compare IFRX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in IFRX's Current Liabilities to $14.54 millions, cumulative Quick Ratio to 1.34 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 485 other companies have achieved higher Quick Ratio than Inflarx N V. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 4635.

Explain Quick Ratio?
How much Cash & cash equivalents IFRX�s has?
What are IFRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 486
Healthcare Sector	# 994
Within the Market	# 4635

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.36	1.19	0.98
(Dec 31 2022)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Rani Therapeutics Holdings Inc	3.66	$ 49.709 Millions	$ 13.566 Millions
Tempest Therapeutics Inc	3.63	$ 7.707 Millions	$ 2.122 Millions
Seaport Therapeutics Inc	3.62	$ 46.242 Millions	$ 12.782 Millions
Genprex Inc	3.60	$ 7.831 Millions	$ 2.175 Millions
Cyclerion Therapeutics Inc	3.60	$ 3.240 Millions	$ 0.900 Millions
Forte Biosciences Inc	3.60	$ 76.957 Millions	$ 21.383 Millions
Cadrenal Therapeutics Inc	3.60	$ 5.710 Millions	$ 1.588 Millions
Renovorx Inc	3.58	$ 7.024 Millions	$ 1.962 Millions
Arrowhead Pharmaceuticals Inc	3.54	$ 692.818 Millions	$ 195.487 Millions
Syndax Pharmaceuticals Inc	3.44	$ 413.686 Millions	$ 120.116 Millions
Alumis inc	3.38	$ 308.501 Millions	$ 91.143 Millions
Quoin Pharmaceuticals Ltd	3.38	$ 18.745 Millions	$ 5.547 Millions
Rhythm Pharmaceuticals Inc	3.38	$ 388.949 Millions	$ 115.197 Millions
Urogen Pharma Ltd	3.32	$ 160.074 Millions	$ 48.225 Millions
Decoy Therapeutics Inc	3.29	$ 13.710 Millions	$ 4.166 Millions
Bolt Biotherapeutics Inc	3.26	$ 27.505 Millions	$ 8.435 Millions
Bullfrog Ai Holdings Inc	3.25	$ 2.184 Millions	$ 0.672 Millions
Madrigal Pharmaceuticals Inc	3.18	$ 983.559 Millions	$ 309.270 Millions
Aclaris Therapeutics Inc	3.17	$ 90.751 Millions	$ 28.645 Millions
Pyxis Oncology Inc	3.16	$ 66.857 Millions	$ 21.131 Millions
Skye Bioscience Inc	3.14	$ 25.737 Millions	$ 8.206 Millions
Acurx Pharmaceuticals inc	3.12	$ 7.556 Millions	$ 2.421 Millions
Gri Bio Inc	3.11	$ 8.229 Millions	$ 2.643 Millions
Cypherpunk Technologies Inc	3.11	$ 14.035 Millions	$ 4.520 Millions
Inhibitor Therapeutics Inc	3.10	$ 2.375 Millions	$ 0.766 Millions
Kyntra Bio Inc	3.04	$ 88.978 Millions	$ 29.242 Millions
Tao Synergies Inc	3.03	$ 5.498 Millions	$ 1.814 Millions
Kala Bio inc	3.03	$ 7.557 Millions	$ 2.494 Millions
Lb Pharmaceuticals Inc	3.01	$ 30.466 Millions	$ 10.126 Millions
Ardelyx inc	2.99	$ 264.689 Millions	$ 88.605 Millions

Date modified: 2026-07-07T11:32:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.